SCHEMBL3100150

SCHEMBL3100150

CCN(C(=O)C(Cc1csc(-c2ccc(F)cc2F)n1)C(=O)NS(=O)(=O)/C=C/c1ccccc1)c1ccccc1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 1/20 0.33
OPRL1 P41146 1/20 0.33
KMT2A Q03164 2/20 0.33
PKM P14618 1/20 0.33
MAPT P10636 4/20 0.33
ALDH1A1 P00352 3/20 0.33
KDM4E B2RXH2 2/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
HTT P42858 2/20 0.32
LMNA P02545 4/20 0.32
GAA P10253 1/20 0.32
MEN1 O00255 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
SCN9A Q15858 1/20 0.31
PTPN2 P17706 1/20 0.31
PTPN1 P18031 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
EIF4E P06730 1/20 0.31
HCRTR1 O43613 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3100159 1.00 OPRM1 (0.33) OPRM1OPRL1KMT2APKMMAPT
SCHEMBL3092693 0.84 KDM4E (0.39) KMT2AMAPTALDH1A1KDM4ENPC1
SCHEMBL3103493 0.81 MAPT (0.37) KMT2AMAPTALDH1A1NPC1RAB9A
SCHEMBL3103499 0.81 MAPT (0.37) KMT2AMAPTALDH1A1NPC1RAB9A
SCHEMBL3100152 0.81 KMT2A (0.41) OPRM1OPRL1KMT2APKMALDH1A1
SCHEMBL3100158 0.81 KMT2A (0.41) OPRM1OPRL1KMT2APKMALDH1A1
SCHEMBL3100563 0.80 MAPT (0.43) OPRM1KMT2APKMMAPTALDH1A1
SCHEMBL3086067 0.80 KMT2A (0.41) KMT2APKMALDH1A1HTTGAA
SCHEMBL3086071 0.80 KMT2A (0.41) KMT2APKMALDH1A1HTTGAA
SCHEMBL3097746 0.79 LMNA (0.41) KMT2APKMHTTLMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 OPRM1 2431/4885OPRL1 2040/4885KMT2A 1948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.